| scholarly article | Q13442814 |
| P50 | author | Susanne Kaser | Q43166190 |
| P2093 | author name string | Claudia Ress | |
| P2860 | cites work | Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease | Q24300844 |
| Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study | Q43039600 | ||
| The impact of liver fat vs visceral fat in determining categories of prediabetes | Q43184911 | ||
| Liver injury in acute fatty liver of pregnancy: possible link to placental mitochondrial dysfunction and oxidative stress. | Q43208286 | ||
| SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis | Q43412126 | ||
| Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease | Q44202802 | ||
| Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation | Q44797080 | ||
| A prospective national study of acute fatty liver of pregnancy in the UK. | Q46336995 | ||
| Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy | Q46405084 | ||
| Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. | Q46442905 | ||
| Alcohol-related problems in Taiwan with particular emphasis on alcoholic liver diseases | Q47759121 | ||
| Perilipin 5 improves hepatic lipotoxicity by inhibiting lipolysis. | Q52653330 | ||
| Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C | Q59273491 | ||
| The role of apolipoprotein A5 in non-alcoholic fatty liver disease | Q61451349 | ||
| Epidemiology of alcoholic liver disease | Q68135451 | ||
| Effects of free fatty acids on the metabolic response to oral fructose in lean healthy humans | Q71115803 | ||
| Acetaldehyde adducts and autoantibodies against VLDL and LDL in alcoholics | Q72922446 | ||
| Nonalcoholic steatohepatitis | Q74424858 | ||
| Host- and disease-specific factors affecting steatosis in chronic hepatitis C | Q77169958 | ||
| Liver failure during pregnancy | Q80234921 | ||
| Energy expenditure and adaptive responses to an acute hypercaloric fat load in humans with lipodystrophy | Q81185058 | ||
| Evaluation and management of non-alcoholic steatohepatitis | Q81545126 | ||
| Lipoprotein lipase expression in livers of morbidly obese patients could be responsible for liver steatosis | Q83508734 | ||
| Apolipoprotein A5 internalized by human adipocytes modulates cellular triglyceride content | Q84424543 | ||
| Perilipin 5: from fatty liver to hepatic lipodystrophy? | Q86047296 | ||
| Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level | Q38347572 | ||
| NAFLD: a multisystem disease. | Q38446387 | ||
| Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism | Q38509473 | ||
| The small GTPase Rab7 as a central regulator of hepatocellular lipophagy | Q38922472 | ||
| Pharmacological activation of aldehyde dehydrogenase 2 by Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice. | Q38925122 | ||
| Hepatitis C virus nonstructural protein 5A favors upregulation of gluconeogenic and lipogenic gene expression leading towards insulin resistance: a metabolic syndrome | Q39062412 | ||
| Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. | Q39118328 | ||
| SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells | Q39791492 | ||
| Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia | Q39975300 | ||
| Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. | Q40463023 | ||
| Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis | Q40960591 | ||
| Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. | Q41191940 | ||
| Alcoholic liver disease: natural history | Q41623292 | ||
| Hepatitis C viral proteins perturb metabolic liver zonation. | Q41739888 | ||
| The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis | Q42010216 | ||
| Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat | Q42088454 | ||
| Hepatitis C virus dysregulates glucose homeostasis by a dual mechanism involving induction of PGC1α and dephosphorylation of FoxO1. | Q42249714 | ||
| Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. | Q42462295 | ||
| A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production | Q42503419 | ||
| Liver specific inactivation of carboxylesterase 3/triacylglycerol hydrolase decreases blood lipids without causing severe steatosis in mice | Q42508123 | ||
| Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans | Q42989310 | ||
| Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. | Q42990025 | ||
| Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity | Q43031928 | ||
| Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis | Q43034053 | ||
| Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy | Q35108275 | ||
| The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice | Q35108391 | ||
| Review article: Nutritional therapy in alcoholic liver disease | Q35206697 | ||
| Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. | Q35213694 | ||
| Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling | Q35235426 | ||
| Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease | Q35239565 | ||
| Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C | Q35522668 | ||
| Peroxisome Proliferator-Activated Receptors, Fatty Acid Oxidation, Steatohepatitis and Hepatocarcinogenesis | Q35550462 | ||
| Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice | Q35659167 | ||
| Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes | Q35837720 | ||
| Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group | Q35841368 | ||
| Relationship between body fat mass and free fatty acid kinetics in men and women. | Q35871368 | ||
| Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice | Q35900825 | ||
| The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome | Q35901803 | ||
| Reversal of muscle insulin resistance by weight reduction in young, lean, insulin-resistant offspring of parents with type 2 diabetes | Q35991365 | ||
| Opposing roles of cell death-inducing DFF45-like effector B and perilipin 2 in controlling hepatic VLDL lipidation | Q36145221 | ||
| PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice | Q36330881 | ||
| Skeletal muscle insulin resistance promotes increased hepatic de novo lipogenesis, hyperlipidemia, and hepatic steatosis in the elderly | Q36339529 | ||
| Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects | Q36588248 | ||
| Histological assessment of non-alcoholic fatty liver disease | Q36634377 | ||
| Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly | Q36913366 | ||
| Non-alcoholic fatty liver disease: the mist gradually clears | Q37096332 | ||
| Insulin resistance, inflammation, and non-alcoholic fatty liver disease | Q37301920 | ||
| Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver | Q37619753 | ||
| Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus | Q37713887 | ||
| Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. | Q37768230 | ||
| Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance | Q37862117 | ||
| Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances | Q37872342 | ||
| Drug-induced hepatic steatosis | Q38216273 | ||
| Recent advances in understanding proteins involved in lipid droplet formation, growth and fusion. | Q38217400 | ||
| A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. | Q38255465 | ||
| Dietary models of insulin resistance | Q38274138 | ||
| Hepatitis C virus and lipid droplets: finding a niche | Q38286433 | ||
| Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection. | Q38290690 | ||
| Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. | Q38302026 | ||
| Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression | Q24606745 | ||
| Endoplasmic reticulum stress and the inflammatory basis of metabolic disease | Q24633352 | ||
| Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation | Q24673179 | ||
| Drug-induced liver injury in obesity | Q26828462 | ||
| Role of mitochondria in nonalcoholic fatty liver disease | Q27028142 | ||
| Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C | Q27477981 | ||
| Advances in understanding and treating liver diseases during pregnancy: A review | Q28080792 | ||
| Hepatic lipid droplet biology: Getting to the root of fatty liver | Q28087033 | ||
| Absence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice | Q28240106 | ||
| Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation | Q28569249 | ||
| Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease | Q28571421 | ||
| Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP) | Q28575163 | ||
| Autophagy regulates lipid metabolism | Q29547421 | ||
| Steatohepatitis: a tale of two "hits"? | Q29547771 | ||
| Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease | Q29614897 | ||
| Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity | Q29614932 | ||
| Molecular mediators of hepatic steatosis and liver injury | Q29616709 | ||
| PPARs and the complex journey to obesity | Q29619271 | ||
| Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease | Q29619334 | ||
| Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
| Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice | Q30881683 | ||
| Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. | Q31040495 | ||
| The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver | Q31449696 | ||
| Modulation of fatty acid and bile acid metabolism by peroxisome proliferator-activated receptor α protects against alcoholic liver disease | Q33717578 | ||
| Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction | Q33775699 | ||
| A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women | Q33863717 | ||
| Pregnancy-related liver disorders | Q33978151 | ||
| Endoplasmic reticulum stress links hepatitis C virus RNA replication to wild-type PGC-1α/liver-specific PGC-1α upregulation | Q34057855 | ||
| Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy | Q34129374 | ||
| Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system | Q34262892 | ||
| Epidemiology of alcoholic liver disease | Q34345871 | ||
| Alcoholic disease: liver and beyond. | Q34405030 | ||
| Adipose triglyceride lipase is a major hepatic lipase that regulates triacylglycerol turnover and fatty acid signaling and partitioning | Q34511046 | ||
| ATGL-catalyzed lipolysis regulates SIRT1 to control PGC-1α/PPAR-α signaling | Q35004298 | ||
| Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity | Q35063067 | ||
| Acute fatty liver of pregnancy: over six months follow-up study of twenty-five patients | Q35069517 | ||
| Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up | Q35090649 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | triglyceride | Q186319 |
| P304 | page(s) | 1664-1673 | |
| P577 | publication date | 2016-01-28 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Mechanisms of intrahepatic triglyceride accumulation | |
| P478 | volume | 22 |
| Q64096895 | A Pathophysiological Model of Non-Alcoholic Fatty Liver Disease Using Precision-Cut Liver Slices |
| Q92578120 | Adipocytes as lipid sensors of oleic acid transport through a functional Caco-2/HT29-MTX intestinal barrier |
| Q90708084 | Curcumin Recovers Intracellular Lipid Droplet Formation Through Increasing Perilipin 5 Gene Expression in Activated Hepatic Stellate Cells In Vitro |
| Q55282555 | Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells. |
| Q47670676 | Hepatic Lipid Accumulation and Nrf2 Expression following Perinatal and Peripubertal Exposure to Bisphenol A in a Mouse Model of Nonalcoholic Liver Disease. |
| Q54226744 | Hepatitis C in Pregnancy. |
| Q48127350 | Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells |
| Q64226476 | Jwa Kum Whan Attenuates Nonalcoholic Fatty Liver Disease by Modulating Glucose Metabolism and the Insulin Signaling Pathway |
| Q42758574 | Mechanisms Involved in Disruption of Adipose Tissue Mass Resulting from Chronic Unhealthy Alcohol Consumption |
| Q59792894 | MicroRNA-124 Regulates Fatty Acid and Triglyceride Homeostasis |
| Q91863612 | Mitochondrial disease disrupts hepatic allostasis and lowers the threshold for immune-mediated liver toxicity |
| Q58551494 | Niacin-Induced Anicteric Microvesicular Steatotic Acute Liver Failure |
| Q91871168 | Orotic acid-treated hepatocellular carcinoma cells resist steatosis by modification of fatty acid metabolism |
| Q94570524 | Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content |
| Q38834079 | Resveratrol alleviates FFA and CCl4 induced apoptosis in HepG2 cells via restoring endoplasmic reticulum stress |
| Q92533825 | S100A16-induced adipogenesis is associated with up-regulation of 11 β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) |
| Q51245978 | Serum lipids as an indicator for the alteration of liver function in patients with hepatitis B. |
| Q46093623 | Systems biology of personalized nutrition |
Search more.